Testing OPB-101 for platinum-resistant ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer (high-grade serous type) must have come back within 6 months of your last platinum-based chemo.
- You must have had at least 2 different types of chemotherapy before, including a platinum-based one.
- Your tumor must be measurable (can be seen on scans).
- You must be able to do your daily activities with little or no help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, OPB-201, for people with endometrial or ovarian cancer that came back after treatment. It is for those whose cancer has a specific marker called PRAME and a certain HLA type.
This trial tests IN10018 together with standard chemotherapy in people with high-grade serous ovarian (or related) cancer that has come back or progressed soon after platinum treatment. The goal is to see if adding IN10018 can improve cancer control and safety.
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
This trial tests a new drug called JSKN003 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if this drug can shrink tumors or slow cancer growth. If you qualify, you may receive this experimental treatment and be closely monitored by a study team.
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
This trial tests a new drug called SYS6043 (which targets a protein called B7-H3 found on some cancer cells) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemotherapy. It compares SYS6043 to standard treatments like paclitaxel or topotecan, and aims to see if it can shrink tumors or slow the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.